ArticleBlood cancer journal2026

Low-dose CD7 chimeric antigen receptor T cells for relapsed/refractory T-cell lymphomas: a single-arm, open-label, phase Ia/Ib study.

Fan Yang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.